Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors.

Waldhorn, Ithai; Holland, Roy; Goshen-Lago, Tal; Benguigui, Madeleine; Halberthal, Michael; Shaked, Yuval; Ben-Aharon, Irit

Waldhorn, Ithai; Holland, Roy; Goshen-Lago, Tal; Benguigui, Madeleine; Halberthal, Michael; Shaked, Yuval; Ben-Aharon, Irit.

Afiliación

Waldhorn I; Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
Holland R; Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
Goshen-Lago T; Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
Benguigui M; Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Halberthal M; Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Shaked Y; General management, Rambam Health Care Campus, Haifa, Israel.
Ben-Aharon I; Rappaport Faculty of Medicine, Technion, Haifa, Israel.

JAMA Oncol ; 8(6): 1-2, 2022 06 01.

Article en En | MEDLINE | ID: mdl-35452089

Asunto(s)

Neoplasias; Vacunas; Vacuna BNT162; Humanos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas / Neoplasias Límite: Humans Idioma: En Revista: JAMA Oncol Año: 2022 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google